Tendon pain is notoriously difficult to treat. Patients cycle through rest, anti-inflammatories, and stretching programmes with inconsistent results, while clinicians are left weighing options that often fall short of resolving the underlying problem. Extracorporeal shockwave therapy (ESWT) has emerged as one of the more compelling additions to the tendinopathy toolkit, but the conversation around it is frequently muddled by overpromising marketing on one side and reflexive scepticism on the other.
The evidence for ESWT extracorporeal shockwave therapy is stronger than many appreciate, but it is also far more specific than most general overviews suggest. Outcomes depend on the condition being treated, the protocol selected, and whether shockwave is integrated with an appropriate rehabilitation programme. Applied correctly, it can deliver meaningful results for Achilles tendinopathy, plantar fascia pain, and gluteal tendinopathy. Applied without clinical precision, those results are considerably less reliable.
This analysis cuts through the noise. Drawing on current clinical evidence including the latest ISMST guidelines, it examines where shockwave therapy genuinely delivers, where the limitations lie, and why specialist-led delivery is the deciding factor between treatment success and disappointment.
What Is Extracorporeal Shockwave Therapy?
Extracorporeal shockwave therapy (ESWT) is a non-invasive treatment that delivers acoustic pressure waves through the skin to targeted musculoskeletal tissue via a handheld applicator. The term “extracorporeal” simply means the energy source remains outside the body. Those mechanical waves pass through soft tissue and trigger a biological healing response at the treatment site, without the need for surgery or injections.
Focused vs Radial ESWT: Not the Same Treatment
Focused ESWT concentrates energy at a defined depth for deeper or focal pathology; radial ESWT disperses energy over a broader surface area, a distinction explored in detail later in this piece.
How ESWT Works
ESWT acts through two primary mechanisms:
- Mechanical tissue regeneration: Shockwaves stimulate tenocyte activity, promote neovascularisation (new blood vessel formation), and drive collagen synthesis, initiating a controlled inflammatory healing response in degenerated or chronically loaded tissue.
- Neurological pain modulation: Repeated acoustic stimulation reduces local nerve sensitivity, including downregulation of substance P, which helps explain why pain relief can occur before structural changes are visible on imaging.
Established, Not Experimental
ESWT has been used in clinical practice for over three decades. It is not a novel or unproven intervention. NICE has issued formal guidance on ESWT for Achilles tendinopathy, and separate Interventional Procedures Guidance covers refractory plantar fasciitis and greater trochanteric pain syndrome. NHS recognition reflects a treatment with a defined evidence base and an acceptable safety profile.
Critically, ESWT is a therapeutic input that works best within a structured treatment pathway, a theme that runs through every condition-specific section that follows.
Shockwave Therapy Benefits: Where the Evidence Is Strongest
The case for ESWT is not built on isolated studies or single-condition trials. A 2022 narrative review examined its use across five common tendinopathies, and the International Society for Medical Shockwave Treatment (ISMST) published its comprehensive 3rd edition guidelines in 2024, covering Achilles tendinopathy, plantar fasciitis, lateral epicondylopathy, patellar tendinopathy, and greater trochanteric pain syndrome. That breadth of coverage reflects a treatment with genuine clinical reach, but the detail within those guidelines tells a more nuanced story.
The evidence consistently favours combined ESWT and structured exercise over shockwave alone, a point developed in the rehabilitation section later (PMC9219268). Condition-specific variability remains meaningful and should inform every treatment decision.
Condition-specific evidence depth matters here. For plantar fasciitis and Achilles tendinopathy, the evidence is well-established, supported by multiple guidelines and NHS recognition. For lateral epicondylopathy and greater trochanteric pain syndrome, the evidence is promising but more conditional, with outcomes more dependent on accurate diagnosis and experienced delivery.
Patellar tendinopathy is the important exception. Expert consensus notes that patellar tendinopathy outcomes require careful evaluation; the appropriate protocol depends on the individual presentation and clinician judgment. In other words, more intervention is not always better, and the optimal protocol depends entirely on the specific diagnosis in front of you.
This variability is precisely why accurate diagnosis precedes everything else. The tendinopathy, its anatomical location, its chronicity, and the patient’s current load tolerance all determine whether ESWT is indicated, and if so, which protocol is appropriate. Blanket shockwave protocols applied without that diagnostic foundation are unlikely to replicate the outcomes seen in guideline-based practice.
Extracorporeal Shockwave Therapy for Achilles Tendinopathy
Achilles tendinopathy is one of the most common presentations at a sports medicine clinic, but the label covers two distinct conditions that require different clinical approaches. Insertional Achilles tendinopathy affects the tendon at its calcaneal attachment and is often associated with compressive load, bony prominences, and a different biomechanical profile. Non-insertional tendinopathy involves the mid-portion of the tendon above the calcaneal insertion. The ISMST guidelines address these as separate clinical entities with separate protocols. Treating them identically is a diagnostic error that directly undermines outcomes.
For non-insertional Achilles tendinopathy, the evidence supporting ESWT is well-established. Combined with eccentric loading or heavy slow resistance training, ESWT is endorsed by clinical guidelines and NICE HealthTech guidance (HTG426) for improving pain, function, and return to activity. The insertional variant is less straightforward; comparative research has found limited benefit from ESWT over conservative management alone in some insertional cases, reinforcing why this distinction is clinically non-negotiable.
In chronic refractory presentations, where conservative management has already failed, ESWT can still achieve meaningful gains. However, prognosis depends on symptom duration, the tendon’s residual load capacity, and patient factors including general health and training history. ESWT is not a reset button; it is a stimulus applied to tissue that still needs to be conditioned through progressive loading.
Before any shockwave treatment at PSM, diagnostic ultrasound is used to confirm the nature and extent of tendon pathology, grade degenerative change, and rule out structural differentials such as partial tears or calcific deposits. This imaging step ensures the intervention is being directed at the correct problem. You can read more about the clinical rationale for this approach in our overview of why shockwave therapy may be appropriate for your condition.
Timing is equally important. Tendinopathy exists on a continuum from reactive through to degenerative, and the phase of pathology determines how ESWT should be integrated with loading rehabilitation. Applying shockwave to an acutely irritable tendon without accounting for its current load tolerance risks a reactive flare. Clinical staging of the tendon, informed by history, examination, and imaging, is a prerequisite for getting this sequence right.
Shockwave Therapy for Plantar Fascia Pain: What the Research Shows
Plantar fasciitis represents one of the most evidence-supported applications of ESWT available. It carries NHS endorsement, features in ISMST clinical guidelines, and is backed by systematic reviews and meta-analyses demonstrating meaningful reductions in heel pain and improvements in function. Royal Orthopaedic Hospital clinical data reports approximately 75 to 80% success rates for heel pain patients treated with shockwave, figures consistent with the broader clinical literature.
Two distinct mechanisms appear to drive these outcomes. At the fascial insertion, ESWT stimulates tenocyte activity and collagen synthesis, promoting genuine tissue-level change. Simultaneously, it modulates pain through neurological pathways, reducing substance P and central sensitisation at the treated site. This dual action explains a pattern commonly observed in practice: pain relief frequently precedes any visible structural change on imaging, which can otherwise seem counterintuitive to patients expecting a straightforward cause-and-effect relationship.
Diagnosis first, treatment second. Plantar heel pain is not a single diagnosis. Fat pad atrophy, calcaneal stress responses, and nerve entrapment conditions such as Baxter’s neuropathy can all produce similar symptoms. Applying shockwave therapy for plantar fascia pain without confirming the specific source is likely to produce a poor result, not because ESWT has failed, but because it was never indicated for that presentation.
A structured ESWT protocol for confirmed plantar fasciitis typically involves multiple sessions, with recent clinical data supporting three sessions per week across a three-week period at defined energy parameters, with outcome assessment at four and twelve weeks. This is not a single-session fix. Stretching, progressive loading, and footwear modification are integral components, and patient adherence to the rehabilitation element is a significant determinant of outcome.
ESWT is generally indicated after an adequate trial of conservative management has been completed without sufficient improvement. Selecting the right patients, at the right stage, with a confirmed diagnosis improves success rates considerably.
ESWT for Gluteal Tendinopathy: An Emerging but Promising Evidence Base
Gluteal tendinopathy sits at the lateral hip, where the gluteus medius and minimus tendons attach to the greater trochanter. It is one of the more frequently misdiagnosed tendinopathies in clinical practice, often labelled as trochanteric bursitis or attributed to lumbar referred pain. That misdiagnosis matters: a randomised controlled trial of 103 patients found bursal distension present in only 8.3% of cases, confirming that primary tendon pathology, not bursitis, is the dominant driver of greater trochanteric pain syndrome. Treating the wrong structure produces predictably poor results.
The evidence for ESWT in this indication is building. Greater trochanteric pain syndrome is listed as an indication in the ISMST guidelines, and a Level I randomised controlled trial demonstrated an 86.8% success rate at two months using focused ESWT combined with a structured exercise protocol, with improvements sustained at follow-up. Research examining combined focused and radial shockwave protocols for gluteus medius tendon pathology has tracked long-term outcomes, reflecting growing sophistication in how ESWT is applied to this condition.
The honest qualification is that the evidence base here is less mature than for Achilles or plantar fascia indications. That does not mean ESWT is unsuitable; it means the margin for diagnostic error is narrower and the requirement for experienced clinical delivery is higher. Generic shockwave provision, applied without imaging confirmation, is unlikely to replicate the results seen in controlled trials.
Differentiating gluteal tendinopathy from trochanteric bursitis, hip joint pathology, and lumbar referral is not straightforward on clinical examination alone. Diagnostic ultrasound or MRI is strongly advisable before committing to a treatment pathway. This is precisely the type of condition where a thorough specialist assessment of tendon conditions before any intervention is non-negotiable rather than precautionary.
As with the other tendinopathies covered in this piece, the trial evidence supports ESWT within a combined approach. Shockwave applied in isolation, without a structured gluteal loading and pelvic stability programme, consistently underperforms relative to integrated treatment. The biological stimulus ESWT provides needs the mechanical reinforcement of progressive rehabilitation to translate into durable functional recovery.
Focused vs Radial ESWT: Why the Distinction Matters Clinically
As introduced in the opening section, focused and radial ESWT are not interchangeable, a principle that the ISMST guidelines formalise across all covered indications.
Not all shockwave devices work the same way. Focused ESWT concentrates acoustic energy at a defined anatomical depth, making it the appropriate choice for deeper structures, focal lesions, or calcific pathology where precision matters. Radial ESWT disperses energy across a broader surface area, which suits more superficial or diffuse presentations.
This distinction is built into the ISMST guidelines, which address device type as part of the protocol recommendation for each covered indication. Using a radial device on a deep focal tendon pathology because that is what is available is not a neutral decision; it is a compromise that reduces the likelihood of a meaningful clinical response. Suboptimal results in non-specialist settings are frequently attributable to exactly this mismatch, rather than to any fundamental failure of ESWT as a treatment.
Well-equipped specialist clinics maintain access to both modalities precisely so that device selection follows clinical diagnosis, not equipment inventory.
Device type is, however, only one variable in a more complex equation. Energy flux density, pulse count, application frequency, and session spacing all independently influence outcomes. The ISMST position is explicit: these parameters require individualisation based on the specific condition, its anatomical presentation, and the patient’s clinical profile. There is no single protocol that transfers cleanly across all tendinopathies, nor across all patients presenting with the same diagnosis.
This is where clinical expertise becomes the determining factor. Selecting the correct device, calibrating the appropriate energy level, structuring the session spacing, and adjusting parameters as treatment progresses all require applied clinical knowledge that goes beyond operating the equipment. The technical complexity of ESWT protocol selection is one of the clearest reasons why the setting in which treatment is delivered has a direct bearing on whether it works.
Side Effects of Shockwave Therapy and Contraindications to Know
Protocol complexity is one dimension of safe ESWT delivery. The other is understanding when not to treat.
Common, expected side effects are well-documented and generally minor. Most patients experience some localised discomfort during the session, followed by temporary soreness or swelling at the treatment site. Minor bruising occurs in some cases. These effects are self-limiting and transient.
Less commonly, patients report skin reddening, or a temporary worsening of symptoms in the first few days after treatment. Rare instances of haematoma or nerve irritation have been documented. When ESWT is performed as recommended, severe complications are not anticipated, but these possibilities form part of the informed consent discussion that should precede any session.
Absolute contraindications require clinical screening before treatment begins:
- Active malignancy in or near the treatment area
- Bleeding disorders or anticoagulant therapy
- Open wounds or active infection at the site
- Pregnancy, particularly where treatment would be applied over the spine or abdomen
- Skeletally immature patients with open growth plates
- Pacemakers or electronic implants in proximity to the treatment site
A recent cortisone injection at the treatment site is a recognised relative contraindication; your clinician will review injection history as part of the pre-treatment assessment. Patients considering shockwave for conditions such as knee tendon pain should disclose any recent injections during assessment.
Taken together, the side-effect and contraindication profile of ESWT is favourable, but only when proper clinical screening is in place. ISMST guidance specifies that clinical examination, relevant imaging, and diagnostic testing are prerequisites before treatment. This is not procedural caution for its own sake; it is what keeps the risk profile low and ensures the right patients receive treatment for the right reasons.
Why Rehabilitation Integration Determines Whether Shockwave Works
Knowing the safety profile of ESWT matters, but safety alone does not determine whether treatment succeeds. ESWT initiates a healing response at tissue level, stimulating tenocyte activity and provoking the early stages of collagen synthesis. But tendon remodelling cannot complete through biological stimulus alone. Progressive mechanical loading is what drives collagen organisation, restores tensile capacity, and translates cellular activity into functional recovery. Without structured loading, the stimulus remains incomplete.
Timing complicates this further. An irritable tendon in a reactive phase responds poorly to high-load exercise; pushing into load too early provokes further sensitisation rather than adaptation. Equally, applying ESWT at inappropriate energy levels or before the tendon is in the right clinical state can blunt rather than support the intended response. Clinical staging of the tendon condition is a prerequisite for sequencing both interventions correctly. This is one of several reasons why protocol decisions require clinical assessment rather than a standard template.
In practice, integrated delivery means ESWT sessions are scheduled within a phased rehabilitation programme rather than booked independently of it. Exercise prescription is adapted to the tendon’s current load tolerance, progressed as capacity improves, and monitored through functional benchmarks. Where clinical uncertainty remains, follow-up imaging can confirm whether structural change is tracking alongside symptomatic improvement.
One expectation is worth setting clearly at the outset. Shockwave is not a passive treatment. The rehabilitation component is load-bearing, not optional. Patients who engage with it achieve better outcomes. Establishing that expectation from the first appointment is part of responsible clinical practice, not a disclaimer.
How PSM Delivers Shockwave Therapy Within a Specialist Pathway
That integration of rehabilitation with ESWT, described in the previous section, only delivers its full value when the clinical environment supports it from the outset. At Pro Sports Medicine, that environment is the starting point, not an added feature.
The PSM Pathway structures every patient journey around accurate diagnosis first. Before ESWT is considered, a thorough clinical assessment establishes what the problem actually is, where it sits within the tendon’s pathological continuum, and what treatment is genuinely indicated. Diagnostic ultrasound is available in-clinic and used where it adds meaningful information, confirming tendon pathology, grading degeneration, and ruling out structural differentials such as partial tears that would alter the treatment decision entirely.
The multidisciplinary setup at PSM is what separates this from a standalone shockwave service. Sports Medicine Doctors, specialist musculoskeletal physiotherapists, and access to consultant-level musculoskeletal radiology operate within the same clinical framework. ESWT, when indicated, sits inside that framework rather than alongside it. The rehabilitation programme is built around the same diagnosis that informed the decision to use shockwave in the first place.
PSM was founded in 2008 with a clear mission: to provide the standard of sports medicine care received by professional and elite athletes to all patients. That background shapes how assessments are conducted and how rehabilitation is programmed, applying the same clinical rigour to a recreational runner with plantar fasciitis as to a professional athlete with Achilles tendinopathy.
Appropriate candidates for ESWT at PSM include patients presenting with Achilles tendinopathy, plantar fasciitis, gluteal tendinopathy, and other relevant tendinopathies, provided they have been assessed, diagnosed, and confirmed as suitable following clinical screening. Patients seeking shockwave without prior assessment are not appropriate candidates, and PSM does not operate that way.
Outcomes vary. Condition, patient factors, and rehabilitation adherence all influence results. PSM’s role is to ensure that when ESWT is indicated, it is delivered in the most evidence-aligned way possible within a pathway designed to maximise the probability of a successful return to activity. As a specialist musculoskeletal clinic in Cardiff, that pathway spans diagnosis through to performance, not treatment in isolation.
The Bottom Line on Shockwave Therapy for Tendon Injuries
The evidence for extracorporeal shockwave therapy is substantial, but it is not uniform. Across the conditions covered in this post, the picture is one of a clinically validated intervention with meaningful boundaries: effective when correctly applied, unreliable when it is not.
As established in the condition-specific sections above, the evidence is most robust for plantar fasciitis and Achilles tendinopathy and more conditional for other presentations. Patient selection, protocol choice, and rehabilitation integration are not procedural details; they are the variables that determine whether treatment succeeds. Choosing between focused and radial ESWT, calibrating energy parameters, staging treatment relative to tendon irritability, and building a concurrent loading programme all require clinical judgement that goes beyond simply owning the equipment. The setting in which ESWT is delivered is therefore directly relevant to the outcome a patient can reasonably expect.
If you are managing a tendon injury that has not responded to initial conservative treatment, a specialist assessment is the appropriate next step. Not to proceed automatically to shockwave, but to confirm the diagnosis, establish whether ESWT is indicated for your specific presentation, and determine where it sits within a structured plan. A persistent tendon problem that has been labelled generically, or treated without imaging confirmation, may not have been correctly identified in the first place.
At Pro Sports Medicine, we offer the diagnostic capability, clinical expertise, and rehabilitation infrastructure to deliver ESWT as the evidence intends. That means accurate diagnosis before any intervention, appropriate protocol selection based on clinical findings, and a rehabilitation pathway structured around your return to activity or performance. For patients in Cardiff, South Wales, and the surrounding region, that level of specialist input is available without the referral delays that often accompany musculoskeletal care.
Shockwave therapy works. The evidence is clear on that. But it works best when it is part of a pathway, not a shortcut around one.
Conclusion
A tendon problem that has not responded to basic management deserves proper investigation, not repeated cycles of the same approach. If you are dealing with a persistent Achilles, plantar fascia, or gluteal tendon injury, a specialist assessment is the logical next step.
Get the diagnosis right. Get the pathway right. Give the treatment the conditions it needs to work. That is how tendon injuries resolve, and that is exactly what we are here to help you do.
